Fact CheckerSign in

NCT06285422Active, not recruitingPhase 1

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

A Phase 1 Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin's Lymphoma (VIVID)

Source: ClinicalTrials.gov · Last updated 28 Nov 2025

Brief summary (registry, in English)

SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

Status (registry)
Active, not recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
6 (estimated)
First submitted
22 Feb 2024
Start date
18 Apr 2024
Primary completion date
Dec 2025
Lead sponsor
Sana Biotechnology
NCT number
NCT06285422

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 6
  • From 18 Apr 2024 to the primary completion date, Dec 2025
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Prior CD22-directed therapy including CD22-directed CAR T cell therapy or other CD22 -directed antibody or cell therapy (e.g., Natural Killer (NK) cell)
  • History of central nervous system (CNS) involvement of lymphoma within 1 year prior to enrollment.
  • Autologous hematopoietic stem cell transplantation (HSCT) within 3 months before treatment with Lymphodepleting (LD) chemotherapy (or allogeneic HSCT at any time)

Other illness

  • Active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as \>10 mg/day prednisone or equivalent)
  • History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement, within 12 months of enrollment.

Who the study is looking for

  • Male or Female Subject aged 18-80 years at the time of signing the informed consent
  • Histologic diagnosis of NHL (based on World Health Organization 2016 criteria) including:
    • LBCL, including Diffuse Large B Cell Lymphoma (DLBCL) not otherwise specified (NOS) (including DLBCL arising from indolent lymphoma), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma (HGBCL), and Follicular Lymphoma (FL) Grade 3B
    • FL
    • Marginal Zone Lymphomas (MZL)
    • Mantle Cell Lymphoma (MCL)
  • Relapsed or refractory disease after no more than 1 prior CD19-directed CAR T cell therapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • At least 1 measurable (PET-positive) lesion per Lugano classification
  • Life expectancy ≥12 Weeks

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
The University of Kansas Hospital
Coordinator of this site? Confirm its status		Kansas CityUnited StatesUnknown status
Swedish Cancer Institute
Coordinator of this site? Confirm its status		SeattleUnited StatesUnknown status
Fred Hutchinson Cancer Center
Coordinator of this site? Confirm its status		SeattleUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.